A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IO-PAZ
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 03 Oct 2017 Planned End Date changed from 19 Oct 2020 to 2 Nov 2020.
- 03 Oct 2017 Planned primary completion date changed from 19 Oct 2020 to 2 Nov 2020.
- 03 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 16 Oct 2017.